SynthesisTravel medicine and infectious disease
Prognostic value of apolipoproteins in COVID-19 patients: A systematic review and meta-analysis.
Synthesis in Travel medicine and infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis.Lipids in health and disease · 2023Pooled it
- Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients.Lipids in health and disease · 2025Article
- Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.Current medicinal chemistry · 2025Article
- The prognostic value of serum apolipoprotein A1 levels in elderly patients withFrontiers in cellular and infection microbiology · 2025Article
- Alterations in plasma proteome during acute COVID-19 and recovery.Molecular medicine (Cambridge, Mass.) · 2024Article
- Complex changes in serum protein levels in COVID-19 convalescents.Scientific reports · 2024Article
- Evaluation of serum and urine biomarkers for severe COVID-19.Frontiers in medicine · 2024Article
- Association of vitamin B12, folate, and homocysteine with COVID-19 severity and mortality: A systematic review and meta-analysis.SAGE open medicine · 2024Review
- Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project.BMC medicine · 2023Article
- Metabolomic and gut microbiome profiles across the spectrum of community-based COVID and non-COVID disease.Scientific reports · 2023Article
- Article
- Alterations in platelet proteome signature and impaired platelet integrin αJournal of thrombosis and haemostasis : JTH · 2023Article
- Correlates with Vaccine Protective Capacity and COVID-19 Disease Symptoms Identified by Serum Proteomics in Vaccinated Individuals.Molecules (Basel, Switzerland) · 2022Article
- C-Reactive Protein-to-Albumin Ratio and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2022Review
- Fibrinogen-to-Albumin Ratio and Blood Urea Nitrogen-to-Albumin Ratio in COVID-19 Patients: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2022Review
- Prognostic value of albumin-to-globulin ratio in COVID-19 patients: A systematic review and meta-analysis.Heliyon · 2022Review
- Article
- COVID19 biomarkers: What did we learn from systematic reviews?Frontiers in cellular and infection microbiology · 2022Review
- Conceptual interpretation and clinical applicability of a systematic review and meta-analysis about prognostic value of apolipoproteins in COVID-19 patients.Travel medicine and infectious diseaseArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApolipoproteins are predictive biomarkers for cardiovascular, neoplasms and cerebrovascular diseases and are postulated as prognostic biomarkers in infectious diseases, as COVID-19. Thus, we assessed the prognosis value of apolipoproteins for COVID-19 severity and mortality.
methodsWe conducted a systematic review and meta-analysis using observational studies that reported the association between apolipoproteins and severity or mortality in COVID-19 patients. Newcastle-Ottawa was used for the quality assessment of included studies. Effects measurements were shown as odds ratios (ORs) with 95% confidence intervals (CIs), and Egger-test was developed for assessing the risk of bias publication.
resultsWe analyzed 12 cohort studies (n = 3580). Patients with low ApoliproteinA1 (ApoA1) (OR 0.35; 95%CI 0.24 to 0.49; P < 0.001) and ApoliproteinB (ApoB) (OR = 0.78; 95%CI 0.69 to 0.87; P < 0.001) values had a higher risk of developing severe disease. ApoB/ApoA1 ratio showed no statistically significant association with higher odds of severity. Low ApoA1 levels were associated with higher odds of all-cause mortality (OR = 0.34; 95%CI 0.20 to 0.57; P < 0.001). ApoB values showed no statistically significant association with a high risk of all-cause mortality.
conclusionWe suggest that adequate levels of ApoA1 and ApoB can be a protective factor for severity in COVID-19, and ApoB/ApoA1 ratio did not show predictive utility for severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.